Vir Biotechnology reports primary endpoint met in Phase 3 ECLIPSE 1 hepatitis delta trial

what happened

Vir Biotechnology reported positive preliminary results from its pivotal Phase 3 ECLIPSE 1 trial. The company is testing elebsiran and tobevibart, given as monthly subcutaneous injections, in adults with chronic hepatitis delta. The findings were presented at AASLD The Liver Meeting 2026 in Denver. This information is according to TradingView.

The trial enrolled 124 patients, randomized 2:1. One group received the drugs, while the other waited for delayed treatment starting at Week 12. The primary endpoint was met: at Week 48, 44% of patients on the combination had undetectable virus and normal ALT levels, versus 0% in the delayed treatment group (p<0.0001). The key secondary endpoint was also met, with 79% of patients reaching undetectable virus.

The company said the regimen was well tolerated, with one Grade 3 treatment-related adverse event and no treatment interruptions or discontinuations. Data from ECLIPSE 2 and ECLIPSE 3 are expected in the first quarter of 2027, and a U.S. FDA submission is planned for mid-2027.

why it matters

For Vir shares, this is a meaningful step: a successful pivotal trial moves the drug closer to registration and strengthens the company's position in a rare-disease niche. The market will compare the combination with the existing treatment bulevirtide, but for most investors the news matters mainly to one company.

market impact

Vir Biotechnology shares: positive pivotal trial data supports interest in the company's stock

• ▲Vir Biotechnology shares pressure up — positive pivotal trial data raises expectations for drug registration

tags

instruments

on polymarket